trending Market Intelligence /marketintelligence/en/news-insights/trending/A6WuRUVKjU86sRGDCAOsjA2 content esgSubNav
In This List

Tvardi Therapeutics names CEO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Tvardi Therapeutics names CEO

Tvardi Therapeutics Inc. said it appointed Imran Alibhai as the company's CEO and board member, effective immediately.

Previously, Alibhai served as senior vice president and managing director at DNAtrix Inc. He was also an investment banker in PJ Solomon LP's healthcare advisory group. In addition, he held investing roles at Accelerator Corp., Alexandria Venture Investments LLC and MPM Capital.

Houston-based Tvardi Therapeutics is a biotechnology company that develops medicines for the treatment of cancer, chronic inflammation and fibrosis.